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Screening and Treatment
Outcomes in Adults and Children
With Type 1 Diabetes and




To describe celiac disease (CD) screening rates and glycemic outcomes of a
gluten-free diet (GFD) in patients with type 1 diabetes who are asymptomatic
for CD.
RESEARCH DESIGN AND METHODS
Asymptomatic patients (8–45 years) were screened for CD. Biopsy-confirmed CD
participants were randomized to GFD or gluten-containing diet (GCD) to assess
changes in HbA1c and continuous glucose monitoring over 12 months.
RESULTS
Adults had higher CD-seropositivity rates than children (6.8% [95%CI 4.9–8.2%,N5
1,298] vs. 4.7% [95%CI 3.4–5.9%,N5 1,089],P5 0.035)with lower rates of prior CD
screening (6.9% vs. 44.2%, P < 0.0001). Fifty-one participants were randomized to a
GFD (N5 27) or GCD (N5 24). No HbA1c differences were seen between the groups
(10.14%, 1.5 mmol/mol; 95% CI 20.79 to 1.08; P 5 0.76), although greater
postprandial glucose increases (4-h 11.5 mmol/L; 95% CI 0.4–2.7; P 5 0.014)
emerged with a GFD.
CONCLUSIONS
CD is frequently observed in asymptomatic patients with type 1 diabetes, and
clinical vigilance is warranted with initiation of a GFD.
Celiac disease (CD) is an immune reaction–mediated condition triggered by gluten, a
protein found in wheat, barley, and rye. CD risk is increased in patients with type 1
diabetes and is characterized by a broad spectrum of presentations, including
gastrointestinal symptoms, growth alterations and anemia, but many patients are
asymptomatic (1–4).
Serologic screening for CD has high sensitivity and specificity, but few reports have
evaluated CD rates and the impact of treatment with a gluten-free diet (GFD) in
asymptomatic CD (aCD) patients with type 1 diabetes. The Celiac Disease and
Diabetes-Dietary InterventionandEvaluationTrial (CD-DIET)prospectively screeneda
large cohortofpatients aged8–45yearswith subsequentengagement in a randomized,
dietary treatment trial to evaluate changes in HbA1c and glycemic variability.
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RESEARCH DESIGN AND METHODS
Recruitment of Participants
Patients aged 8–45 years with type 1
diabetes ($1-year duration) were ap-
proached to undergo CD testing at 22 di-
abetes centers in Ontario, Canada as part
of the CD-DIET Study (clinicaltrials.gov,
NCT01566110) (5). Exclusion criteria in-
cluded CD symptoms (gastrointestinal
symptomology or evidence of growth
impairment, anemia, or osteoporosis), a
previous CD diagnosis, and pregnancy.
CD Screening
Eligible participants (Supplementary
Fig. 1) were screened using tissue trans-
glutaminase IgA (TTG-IgA; Inova Diag-
nostics). CD-seropositive (TTG-IgA$30
chemiluminescent units [CU]) participants
progressed to a gastroenterology consul-
tation with centralized biopsy confirma-
tion (Marsh score $2).
Dietary Intervention Study
Interested participants with biopsy-con-
firmed CD were randomized in a 1:1 ratio
to a GFD or a gluten-containing diet (GCD)
and followed for 1 year. Study visits with
a dietitian occurred every 3 months using
a standardized educational curriculum.
Dietary adherence was also evaluated
through quantification of dietary gluten
intake and repeat TTG-IgA testing. Safety
laboratory tests were evaluated (see
Supplementary Appendix) with monitor-
ing of growth, symptomology, and preg-
nancy. GCD participants who became
symptomatic were transitioned to a
GFD with the completion of outcome
measures. A Data Safety Monitoring
Committee evaluated adverse events.
The primary outcome of CD-DIET was
the change in HbA1c from baseline to 12
months. HbA1c was assessed centrally at
baseline and at 6 and 12 months, with
additional testing by local laboratories.
Continuous glucose monitoring (CGM)
was conducted using the iPro2 CGM
system (Medtronic Inc.) for blinded
assessment.
Analysis was by intention to treat.
Longitudinal differences in HbA1c be-
tween groups were analyzed using the
difference in differences approach and
confirmed using linear mixed effects re-
gression. CGM results were summarized
using standard parametric methods,
while paired t tests were used to assess
within-group differences in HbA1c and
postprandial glucose levels. All analyses
were completed using R Statistics 3.5.1.
A sample size of n 5 60 (30 patients
per arm) was determined to be sufficient
for our between-group analysis to reach
80% power at a 5% significance level un-
der two-sided conditions. Paired analysis
of HbA1c in the GFD arm, a sample size of
n 5 25 before versus after pairs reached
a power above 80% using a two-sided
paired t test with significance set at
P 5 0.05.
RESULTS
Recruitment and CD Screening
Overall, 2,585 patients consented and
2,387 subjects completed CD screening,
including 1,298 adults (54.4%, 19–45
years) and 1,089 children (45.6%, 8–18
years) (see Supplementary Appendix).
Higher rates of any prior CD serologic
screening were seen in pediatric partici-
pants (n5 475, 43.6%, 95%CI 40.7–46.5%)
as compared with adult participants
(n 5 89, 6.9%, 95% CI 5.5–8.3%) (odds
ratio [OR] 10.5, P , 0.0001) (Fig. 1A).
Adults had higher CD-seropositivity
rates (n 5 88, 6.8%; 95% CI 5.4–8.2%)
compared with children (n 5 51; 4.7%;
OR5 1.48, 95% CI 3.4–5.9%, P5 0.035),
but rates did not differ within each
age group on the basis of previous CD
screening status. Biopsies were com-
pleted in 104 participants, and 82 were
confirmed by biopsy with CD-biopsy-
positivity rates of 4.2% (n 5 54; 95%
CI 3.1–5.3%) and 2.6% (n 5 28; 95%
Figure 1—The results from the CD-DIET screening of asymptomatic patients with type 1 diabetes.
A: The percentage of participants previously (black bars) and nonpreviously (white bars) screened
for CD by age group showing lower screening rates in adults (6.9% vs. 44.2%, P, 0.0001). B: CD
serology- (TTG-IgA) and CD biopsy-confirmed rates of CD among the 2,387 subjects screened.
Hatched bars indicate combined rates of CD serology and biopsy positivity, black bars illustrate
pediatric data (8–18 years,N51,089),whilewhitebars showadult rates (19–44 years,N51,298).
Error bars represent 95% CIs. *Significant differences below P , 0.05.
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CI 1.6–3.5%) for adult and pediatric par-
ticipants (OR5 1.64, P5 0.042) (Fig. 1B).
Dietary Intervention Study
The 51 participants were randomized
into the intervention phase, with 27 to
the GFD group and 24 to the GCD group.
Adherence to the assigned diet, as as-
sessedby serialmeasures of gluten intake
and TTG antibody titers, was deemed ex-
cellent (Fig. 2A).Ultimately,weobservedno
longitudinal difference in HbA1c between
the GFD group and GCD group (10.14%
[1.5mmol/mol], 95% CI20.79 to 1.08, P5
0.76). Within the GFD group, an increase in
HbA1c of 10.30% (3.3 mmol/mol) was
observed over 12 months (95% CI 0.04–
0.57%, P 5 0.028) (Fig. 2B).
Using blinded CGM, no differences
were seen in the percentage of time
spent in hypoglycemic, euglycemic, or hy-
perglycemic ranges at 12 months. Despite
this, postprandial glycemia was higher
with the GFD relative to premeal levels at
boththe2-h(11.6mmol/L,95%CI0.7–2.6,
P 5 0.0015) and 4-h (11.5 mmol/L, 95%
CI 0.4–2.7, P 5 0.014) time points, while
glucose levels of the GCD arm returned to
premeal levels (D50.1mmol/L after 4 h;
95% CI 20.8 to 1.0) (Fig. 2C). No differ-
ences in growth parameters (including
height, weight, or BMI in children and
adults, Supplementary Figs. 2 and 3) nor
total daily insulin dose or total daily
insulin dose per kg were observed be-
tween groups.
Hypoglycemic adverse events that were
nonsevere were reported with the GCD
group (N5 3, 12.5%), with none reported
with the GFD group (P 5 0.097).
CONCLUSIONS
This study describes screening and treat-
ment outcomes from a large prospective
assessment of adult and pediatric patients
with type 1 diabetes with aCD. We ob-
served high rates of aCD with 1.5-fold
higher rates in adults as compared with
children. This is consistentwith increasing
rates ofCD inadults (6) and changes in the
symptom profile toward a more subtle
and less classical malabsorptive presen-
tationwith increasing age (7). In addition,
age-related increases in autoimmune co-
morbidities are also well recognized, with
recent T1D Exchange clinic registry data
confirming rising rates of autoimmune
comorbidities from adolescence into
adulthood (8,9).
Adult participants in our study were
also less likely to be screened for CD than
children. This may reflect a lack of clarity
about CD screening recommendations in
adults and the absence of outcome stud-
ies in this population. Current North
Americandiabetes guidelines advise con-
sideration of screening patients with
type 1 diabetes for CD, but actual details
regarding screening tests, timing, and
intervals are only explicitly described
for children (10,11).
Dietary intervention with a GFD did
not result in a difference in HbA1c be-
tween randomized groups but led to
greater postprandial glucose excursions
relative to a GCD. These changes are
consistentwithmucosal recovery,which
can be prolonged (1–3 years), with sub-
sequent improvements in absorption
(2,12). Nonetheless, transition to a GFD
was safe with no significant differ-
ences observed in hypoglycemic time
or adverse events.
Strengths of this report include the
large number of patients screened and
the rigor in delineating an asymptomatic
cohort. In addition, participants in the
intervention phase, who were provided
with frequent dietitian-based support,
exhibited clear differences in gluten in-
take and follow-up TTG serology. Limi-
tations of this study include a small
sample size and the heterogeneity of
participant characteristics that limits
generalization of these findings. In addi-
tion, our data do not represent the
prevalence rates, as we were challenged
by enumeration of the complete popu-
lation at risk in the clinics where screen-
ing was completed. It was also our
experience that despite facilitated and
no-cost access to care, many asymptom-
atic participants were overwhelmed by
the diagnostic process and by the pros-
pect of managing these two conditions,
eachwith significant lifestyle implications.
In summary, diabetes clinicians should
be aware of CD as an important auto-
immune comorbidity of type 1 diabetes
that is frequently asymptomatic. In ad-
dition, clinical vigilance is warranted dur-
ing dietary transition, as GFD-treatment
mayimpactshort-termglycemicvariability.
Figure 2—The results from theCD-DIETDietary Intervention Trial. Data from theGFDarmshown in blackwith a dashed line (▪),while data from theGCD
are shownwith solidgray line (▪).A: Dietaryadherence toassignedgroupwasassessedusing serial serologic testing.TTG-IgAantibody titersweresimilar
in the GCD and the GFD groups at baseline. They appropriately decreased in the GFD arm by 6months and continued to drop among GFDs, resulting in
a significant difference between GCDs (1,698.06 1,834.0 CU) and GFDs (73.46 83.9 CU) at 12months (P, 0.0001). B: The change in HbA1c between
study groups. No difference in HbA1c was seen between the the GFD group relative those on a GCD over the 12months (10.14% [1.5 mmol/mol], P5
0.76); however, within the GFD group, HbA1c increased (10.30% [3.3 mmol/mol], 95% CI 0.04–0.57%, P5 0.028). C: Changes in postprandial glucose
assessed by CGM. Postprandial glycemia in theGFDwas higher comparedwith premeal levels at both the 2-h time point (11.6mmol/L [29mg/dL]; P5
0.0015) and 4-h time point (11.5 mmol/L [27 mg/dL]; P5 0.014), while glucose levels of the GCD arm returned to premeal levels (D5 0.1 mmol/L
[1.8 mg/dL]). Error bars represent 95% CIs. *Significant differences below P , 0.05.
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Given the additional risks for CD-related
microvascular and bone complications,
longitudinal studies are also needed to
assess the clinical impact of this double
diagnosis across the patient’s life span
(13–15).
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